Category: Multi-Slide Guides

The Digest’s 2024 Multi-Slide Guide to Origin Materials, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Origin Materials, the investment perspective

September 15, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Novonesis, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Novonesis, the investment perspective

September 12, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Yield10 Biosciences, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Yield10 Biosciences, the investment perspective

September 11, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Opal Fuels, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Opal Fuels, the investment perspective

September 10, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Ginkgo BioWorks, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Ginkgo BioWorks, the investment perspective

September 9, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Green Plains, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Green Plains, the investment perspective

September 6, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Aemetis, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Aemetis, the investment perspective

September 5, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Neste, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Neste, the investment perspective

September 4, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Gevo, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Gevo, the investment perspective

September 3, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to LanzaTech, the investment perspective

The Digest’s 2024 Multi-Slide Guide to LanzaTech, the investment perspective

September 2, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

}